Cancer Research The Future of Cancer Research: Science and Patient Impact  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 33, 3091-3095, December 1, 1973]
© 1973 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drewinko, B.
Right arrow Articles by Gottlieb, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drewinko, B.
Right arrow Articles by Gottlieb, J. A.

The Effect of cis-Diamminedichloroplatinum(II) on Cultured Human Lymphoma Cells and Its Therapeutic Implications1

B. Drewinko, B. W. Brown and J. A. Gottlieb

Departments of Clinical Chemistry and Laboratory Medicine [B. D.], Biomathematics [B. W. B.], and Developmental Therapeutics [J. A. G.], M.D. Anderson Hospital and Tumor Institute, Houston, Texas 77025

Asynchronous human lymphoma cells treated for 1 hr with increasing concentrations of cis-diamminedichloroplatinum(II) (DDP) revealed a marked decrease in survival as estimated by the colony-forming technique. When the treatment was extended for 8 hr, a killing effect (more than 3 log decades) was observed for a concentration of 5 µg/ml similar to that obtained with 50 µg/ml incubated with the cells for 1 hr. This finding suggests that better antitumor results with less toxic effects may be obtained clinically by prolonged infusion of low doses of DDP.

Synchronized lymphoma cells showed no significant degree of cell cycle stage sensitivity to DDP. The drug kills cells with similar efficiency in all stages of the cell cycle. No killing effect was elicited after incubation of the cells with spironolactone, a compound said to protect the kidneys from the toxic effect of heavy metals. However, simultaneous incubation of spironolactone and DDP did not prevent the lethal action of the second drug. If spironolactone is proven an inhibitor of DDP nephrotoxicity, it will become a valuable addition to the treatment of human neoplasias with DDP.

1 Supported by USPHS Grants RR-05511-10 and CA-10379-06. Presented in part at The Second International Symposium on Platinum Coordination Complexes in Cancer Chemotherapy, Oxford, England, April 1973.

Received 6/27/73. Accepted 8/ 6/73.




This article has been cited by other articles:


Home page
Jpn J Clin OncolHome page
K. Hayashi, N. Ando, H. Watanabe, H. Ide, K. Nagai, N. Aoyama, W. Takiyama, K. Ishida, K. Isono, H. Makuuchi, et al.
Phase II Evaluation of Protracted Infusion of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407)
Jpn. J. Clin. Oncol., September 1, 2001; 31(9): 419 - 423.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1973 by the American Association for Cancer Research.